The Ozempic NAION Lawsuit: What the Vision-Loss Cases Actually Allege

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited

Key Takeaways

• NAION lawsuits allege that Novo Nordisk failed to warn of an elevated risk of nonarteritic anterior ischemic optic neuropathy in patients taking semaglutide.
• The scientific anchor is a July 2024 JAMA Ophthalmology retrospective cohort study by Hathaway, Shah, and colleagues at Massachusetts Eye and Ear and Harvard Medical School.
• NAION causes sudden, usually permanent vision loss in one eye. Established risk factors include small optic disc anatomy, diabetes, hypertension, sleep apnea, and prior NAION in the other eye.
• As of May 2026 the FDA had not added NAION to US semaglutide labeling but was reviewing the signal. Some non-US regulatory communications referenced it.
• NAION cases may proceed within MDL No. 3094 or in separate state-court actions. They are legally distinct from the gastroparesis cases that anchor the MDL.

Direct answer

The Ozempic NAION lawsuit is a developing branch of GLP-1 product-liability litigation alleging that Novo Nordisk failed to warn of an increased risk of nonarteritic anterior ischemic optic neuropathy in semaglutide users. The cases follow a July 2024 JAMA Ophthalmology study reporting elevated NAION hazard among patients prescribed semaglutide. The litigation is in pretrial stages, the science is still being replicated, and the FDA is reviewing the signal as of May 2026.

Table of contents

1. What NAION is, in plain terms
2. The Hathaway et al. 2024 study and what it actually showed
3. The biological plausibility argument
4. What the lawsuits allege
5. What the defense will argue
6. Who is at higher risk of NAION
7. How NAION presents to a patient
8. What the FDA has done so far
9. What to do if you have vascular risk factors and are on a GLP-1
10. The contrary view: why the signal may be smaller than headlines suggest
11. FAQ
12. Sources

What NAION is, in plain terms

The optic nerve carries visual information from the eye to the brain. The anterior portion of that nerve is fed by small blood vessels with limited collateral supply. When perfusion to the optic disc drops below a critical threshold, the nerve fibers die in a wedge-shaped pattern. The result is sudden vision loss, usually in one eye, often noticed on waking.

NAION is non-arteritic, meaning it is not caused by inflammation of the temporal arteries (which is the arteritic form, a separate condition driven by giant-cell arteritis). NAION is the most common cause of sudden optic nerve damage in adults over 50.

The deficit is typically:

• Painless.
• Permanent or only partially recoverable.
• Confined to one eye initially, with a 15 to 20 percent risk to the second eye over years.

The Hathaway et al. 2024 study and what it actually showed

The study published in JAMA Ophthalmology in July 2024 by Hathaway, Shah, Hathaway, Wang and colleagues used a retrospective cohort from a tertiary eye care system in Massachusetts. The analysis compared NAION incidence in patients prescribed semaglutide with patients prescribed non-GLP-1 medications, using propensity matching to adjust for confounders.

The headline findings, as reported in the paper:

• Higher cumulative incidence of NAION in the semaglutide cohort than in matched controls.
• Hazard ratios that were larger in patients prescribed semaglutide for obesity than for those prescribed for diabetes.
• The signal was strongest in the first year of treatment.

What the study did not establish:

• Causation in any individual case.
• A confirmed mechanism by which semaglutide causes NAION.
• Replication across geographies or patient populations beyond the Massachusetts cohort.

The paper's authors explicitly framed the work as hypothesis-generating, recommending additional studies and pharmacovigilance review.

The biological plausibility argument

Plaintiffs and their experts argue that an association between semaglutide and NAION is biologically plausible. The proposed pathways include:

• Rapid glycemic changes. Sharp drops in blood glucose can transiently affect optic nerve perfusion. Diabetic patients starting any potent glucose-lowering therapy may be at temporary risk.
• Rapid weight loss and hemodynamic shifts. Substantial weight loss can change blood pressure, fluid status, and vascular tone in ways that affect end-organ perfusion.
• Sleep apnea unmasking. Patients beginning GLP-1 therapy often have underlying sleep apnea; perfusion deficits during sleep are a known NAION risk factor.

These are hypotheses, not proven mechanisms. The defense view is that hypothesizing a mechanism is not the same as demonstrating one in the dose ranges and time courses of semaglutide therapy.

What the lawsuits allege

NAION complaints generally allege the same elements as other failure-to-warn pharmaceutical cases.

1. Duty. Novo Nordisk had a duty to warn prescribers and patients of foreseeable serious risks.
2. Breach. The semaglutide label did not warn of NAION, even though, in plaintiffs' view, the manufacturer knew or should have known of the risk by some point before the plaintiff's injury.
3. Causation. Semaglutide caused the plaintiff's NAION (specific causation), drawing on the general-causation evidence in the JAMA Ophthalmology paper and supporting expert testimony.
4. Damages. The vision loss is permanent and produces lost wages, medical expenses, and noneconomic harm.

Some complaints also include claims for negligent design or for failure to perform adequate postmarketing surveillance.

What the defense will argue

Novo Nordisk's defense rests on several converging arguments.

Argument 1: One retrospective study is not enough. Single-center retrospective cohorts have well-known biases. The Hathaway paper's findings need replication across geographies and populations before they support a class label change, let alone causation in individual cases.

Argument 2: Confounding is hard to fully eliminate. Patients prescribed semaglutide tend to have diabetes, obesity, hypertension, and sleep apnea. Each is an NAION risk factor independent of any medication.

Argument 3: Background rates matter. NAION is uncommon. Even with elevated relative risk, the absolute number of additional cases in any individual patient population may be small.

Argument 4: Learned intermediary doctrine. Prescribers are expected to evaluate vascular risk factors and counsel patients accordingly. The doctrine, applied in most US states, can shield the manufacturer when adequate information was made available to prescribers.

None of these arguments forecloses plaintiff recovery. They explain why the cases will be contested case by case.

Who is at higher risk of NAION

The risk-factor profile for NAION is well established in ophthalmology literature.

Risk factor	Mechanism	Practical implication
Small or crowded optic disc	Anatomic predisposition; less room for swelling	Documentable on dilated exam
Obstructive sleep apnea	Nocturnal hypoxia and pressure swings	Treat the apnea
Hypertension	Microvascular disease	Optimize control
Diabetes	Microvascular disease and autonomic dysregulation	Optimize control
Use of PDE-5 inhibitors	Possible association in some studies	Discuss with prescriber if relevant
Prior NAION in the other eye	Anatomic and physiologic patterning	High vigilance

How NAION presents to a patient

NAION classically presents with sudden, painless loss of vision in one eye, often noticed when the patient wakes up or first looks in a mirror. The visual deficit is usually a horizontal field defect (more often the lower half of the field) or a generalized blur and dimness in the affected eye.

Patients sometimes describe:

• A "gray curtain" or "dark patch" in one eye.
• Difficulty reading because part of a line is missing.
• Color desaturation in the affected eye.
• Normal vision in the unaffected eye.

Any sudden vision loss is an emergency. The differential includes retinal artery occlusion, retinal detachment, optic neuritis, and arteritic optic neuropathy (giant-cell arteritis), all of which require urgent evaluation. Patients should call their ophthalmologist or go to an emergency department immediately rather than waiting.

What the FDA has done so far

The FDA's response to the NAION signal has been measured.

• After the July 2024 JAMA Ophthalmology publication, the agency initiated a class-wide review of GLP-1 receptor agonists.
• The semaglutide US label had not been updated to include NAION as of May 2026.
• Some non-US regulators have flagged the signal in their own communications, framing it as under review rather than as a confirmed adverse reaction.
• The September 2023 ileus label update is a precedent showing how the FDA handles confirmed postmarketing signals; an analogous NAION update would require similar evidentiary support.

What to do if you have vascular risk factors and are on a GLP-1

The actionable steps are practical.

1. List your risk factors honestly with your prescriber: age, family history, sleep apnea, hypertension, diabetes, prior optic nerve issues, prior NAION in the other eye.
2. Ask about a baseline ophthalmologic exam, particularly if you have not had one in the past year and you have a small or crowded optic disc.
3. Treat sleep apnea aggressively. CPAP adherence reduces nocturnal hypoxia and may lower NAION risk independent of medication.
4. Monitor for symptoms: sudden vision change, especially noticed on waking, in one eye.
5. If symptoms occur, do not wait. Seek same-day ophthalmology evaluation or emergency care.

These are general considerations. Specific risk-benefit decisions belong with your clinician.

The contrary view: why the signal may be smaller than headlines suggest

For balance, the strongest case for caution about the NAION signal.

Point 1: Replication is incomplete. Single retrospective studies, even from strong institutions, are subject to confounding that can survive propensity matching. Replication in independent cohorts using different data sources is essential. Through early 2026 the replication picture was mixed.

Point 2: Absolute risk is small. Even if relative risk is elevated, the population baseline NAION rate is low. Many users will gain meaningful metabolic benefit with no eye consequences.

Point 3: Diabetes itself raises NAION risk. Untreated or poorly controlled diabetes increases NAION risk. The right comparison is not "GLP-1 versus nothing" but "GLP-1 versus alternative therapy in the same patient."

Point 4: Lawsuits scale faster than science. Litigation can proceed long before causation is settled. A growing case count does not equate to growing scientific consensus.

The reasonable position is informed vigilance: take the signal seriously enough to manage risk factors and seek prompt evaluation of any vision change, without treating one retrospective study as proof of universal harm.

Compounded medication note for this topic

For The Ozempic NAION Lawsuit: What the Vision-Loss Cases Actually Allege, keep the pharmacy distinction clear: when compounded semaglutide or tirzepatide is prescribed, it is prepared for an individual patient by a licensed 503A compounding pharmacy. Compounded preparations are not FDA-approved drug products and are not interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound.

The practical question is not whether a compounded medication is a brand substitute. It is whether the prescription, pharmacy label, concentration, follow-up plan, and adverse-event support are clear enough for your specific medical history.

FAQ

What is the Ozempic NAION lawsuit? A growing set of failure-to-warn claims alleging that Novo Nordisk did not adequately warn of an elevated NAION risk in semaglutide users, anchored on the July 2024 JAMA Ophthalmology study.

Is the NAION lawsuit part of the MDL? Some NAION cases may be filed within MDL No. 3094 in the Eastern District of Pennsylvania; others may proceed in state courts. The procedural structure depends on jurisdiction and counsel strategy.

What did the JAMA Ophthalmology paper actually find? Higher NAION hazard in patients prescribed semaglutide compared with propensity-matched controls, with the strongest signal in the obesity-prescribed cohort and within the first year of treatment.

Can NAION be cured? No proven treatment reliably restores vision. Some recovery occurs in a subset of patients over months. The standard of care emphasizes risk-factor management to protect the fellow eye.

If I have sleep apnea, should I avoid Ozempic? Sleep apnea is a recognized NAION risk factor. Treating apnea aggressively (CPAP adherence) is the most important step regardless of medication. Discuss the combination with your clinician.

Has the FDA added NAION to the label? Not as of May 2026 in the US. The agency was reviewing the signal. Other regulators have flagged it as under review.

Is the NAION signal limited to Ozempic? The class-effect question is open. The Hathaway study focused on semaglutide. Whether similar signals exist for tirzepatide and other GLP-1 receptor agonists is under investigation.

Should I stop Ozempic to protect my vision? Discontinuation decisions belong with your clinician. If you have multiple NAION risk factors, the conversation is worth having; abrupt discontinuation has its own consequences.

How do I know if I had NAION? Sudden, usually painless, monocular vision loss requires urgent ophthalmology evaluation. Diagnosis is made on examination, including optic disc appearance, visual field testing, and OCT imaging.

Related guides

• Has Anyone Gotten Thyroid Cancer From Ozempic? What the Cases and the Studies Actually Show
• Does Ozempic Cause Hair Loss? What the Trial Data Actually Shows
• Does Ozempic Cause Blindness? The NAION Signal, Honestly Explained
• The Blurry Eyes Phase: Why Ozempic Makes Vision Hazy and When It Clears
• Is Ozempic Facing a Lawsuit? Mapping the 2026 Litigation Landscape
• Is Ozempic Facing a $2 Billion Lawsuit? Separating the Headline From the Filings

Sources

1. Hathaway JT, Shah MP, Hathaway DB, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology. 2024.
2. Judicial Panel on Multidistrict Litigation. In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094.
3. US District Court for the Eastern District of Pennsylvania. MDL No. 3094 docket.
4. Hayreh SS. Ischemic Optic Neuropathies. Eye. 2004 and subsequent reviews.
5. Ischemic Optic Neuropathy Decompression Trial Research Group. Optic Nerve Decompression Surgery for Nonarteritic Anterior Ischemic Optic Neuropathy. JAMA. 1995.
6. American Academy of Ophthalmology. Preferred Practice Pattern: Nonarteritic Anterior Ischemic Optic Neuropathy. Current edition.
7. US Food and Drug Administration. Ozempic Prescribing Information. Postmarketing adverse reactions section.
8. US Food and Drug Administration. Ileus added to semaglutide postmarketing adverse reactions, September 2023.
9. European Medicines Agency. PRAC communications on GLP-1 receptor agonist safety, 2024-2025.
10. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
11. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
12. American Diabetes Association. Standards of Care in Diabetes, 2025 edition.
13. Restatement (Third) of Torts: Products Liability. Section 6 (learned intermediary).

Footer disclaimers

Platform Disclaimer. FormBlends provides educational information about pending litigation and clinical signals. We do not provide legal advice. Questions about specific cases or claims belong with a licensed attorney in your jurisdiction.

Compounded Medication Notice. Compounded semaglutide is not FDA-approved and is prepared by state-licensed compounding pharmacies under individual prescriptions. The NAION signal discussed in this article was identified in patients using the brand-name product; data on compounded semaglutide are limited.

Results Disclaimer. Discussion of risks and outcomes reflects published research and pending allegations, not certainties for any individual patient. Clinical decisions should be made with a treating clinician.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Saxenda, and Victoza are registered trademarks of Novo Nordisk A/S. Mounjaro, Zepbound, and Trulicity are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by either manufacturer.